<DOC>
	<DOCNO>NCT00489606</DOCNO>
	<brief_summary>To assess pharamcodynamic effect coadministrated SK3530 ( PDE5 inhibitor ) tamsulosin , phase I study healthy volunteer design .</brief_summary>
	<brief_title>Phase I Study Investigate Drug Interaction After Oral Administration Tamsulosin SK3530</brief_title>
	<detailed_description>During two period randomize , double-blind , placebo-controlled , crossover study , 16 healthy men receive tamsulosin 0.2 mg daily 7 day either single 100 mg SK3530 placebo day7 . The blood pressure heart rate monitor 24 hour SK3530 placebo .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>age 20 50 body weight IBMÂ±20 % cardiovascular disease colorblindness weakness hypotension , hypertension , orthostatic hypertension abmormal QTc ( &gt; 430 m )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>SK3530</keyword>
	<keyword>tamsulosin</keyword>
	<keyword>hemodynamic interaction</keyword>
	<keyword>safety</keyword>
</DOC>